Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM8RI3
|
|||
| Drug Name |
GSK3494245
|
|||
| Synonyms |
GSK3494245; DDD01305143; GSK-3494245; DDD-01305143; T7XAE9Y6B9; 2080410-41-7; N-(4-Fluoro-3-(3-morpholinoimidazo(1,2-a)pyrimidin-7-yl)phenyl)pyrrolidine-1-carboxamide; N-(4-fluoro-3-(3-morpholinoimidazo[1,2-a]pyrimidin-7-yl)phenyl)pyrrolidine-1-carboxamide; 1-Pyrrolidinecarboxamide, N-(4-fluoro-3-(3-(4-morpholinyl)imidazo(1,2-a)pyrimidin-7-yl)phenyl)-; N-(4-Fluoro-3-(3-(4-morpholinyl)imidazo(1,2-a)pyrimidin-7-yl)phenyl)-1-pyrrolidinecarboxamide; UNII-T7XAE9Y6B9; CHEMBL5095239; SCHEMBL18495650; BDBM50601512; MS-27077; HY-127102; CS-0093101; GSK3494245/DDD01305143
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Visceral leishmaniasis [ICD-11: 1F54.0; ICD-10: B55.0; ICD-9: 85] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23FN6O2
|
|||
| Canonical SMILES |
C1CCN(C1)C(=O)NC2=CC(=C(C=C2)F)C3=NC4=NC=C(N4C=C3)N5CCOCC5
|
|||
| InChI |
InChI=1S/C21H23FN6O2/c22-17-4-3-15(24-21(29)27-6-1-2-7-27)13-16(17)18-5-8-28-19(14-23-20(28)25-18)26-9-11-30-12-10-26/h3-5,8,13-14H,1-2,6-7,9-12H2,(H,24,29)
|
|||
| InChIKey |
SAJUCKZZYFFICP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteasome (PS) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04504435) A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.